A positive rubella test means your blood contains antibodies against the rubella virus, but what that actually tells you depends on which type of antibody showed up. If the test found IgG antibodies, you almost certainly have immunity, whether from a past infection or from vaccination. If it found IgM antibodies, the picture gets more complicated: it could signal a recent or active infection, but it could also be a false alarm. The distinction matters enormously if you are pregnant or planning to become pregnant, and the interpretation is less straightforward than most people expect.
The Two Antibodies That Change Everything
Standard rubella blood tests look for two classes of antibodies. IgG antibodies are the long-term memory of your immune system. They appear a couple of weeks after infection or vaccination and generally stick around for life. A positive IgG result on a routine screening usually means you are protected against rubella and do not need further vaccination. For most people getting tested before travel, during a workplace health screen, or as part of preconception planning, a positive IgG is the reassuring result they are hoping for.
IgM antibodies are the short-term responders. They spike during an active or very recent infection and usually fade within a few weeks to months. A positive IgM result is what raises red flags, because it can suggest the virus is currently circulating in your body or was there recently. In practice, though, IgM-positive results are surprisingly unreliable in certain settings, a point that deserves its own discussion.
When a Positive IgM Result Is Not What It Seems
One of the biggest pitfalls in rubella testing is that a positive IgM result does not automatically mean you have rubella. In countries where vaccination programs have driven rubella rates very low, the chance that a positive IgM reflects an actual rubella infection has dropped dramatically. A seven-year review by the French National Reference Laboratory for Rubella found that the positive predictive value of a rubella IgM result for diagnosing a true primary infection in pregnant women was only about 1.4%. Even IgG seroconversion, which is normally considered stronger evidence, had a positive predictive value of just 0.2%.1PubMed. Positive predictive value of seroconversion or positive rubella IgM in diagnosis of maternal rubella infection: Seven-years review of French National Reference Laboratory for Rubella In plain terms, the vast majority of those “positive” results were not rubella at all.
Several things can cause a false-positive IgM. Other viral infections can trigger cross-reactive antibodies that light up on a rubella test. Some people produce persistent IgM that lingers for months or even years after an old infection or vaccination, without any active virus present. A case report documented a woman who tested IgM-positive during two separate pregnancies with no evidence of fetal infection either time, illustrating how persistent or nonspecific IgM can recur and create unnecessary alarm.2PubMed Central. Repeated Detection of Rubella Virus IgM Antibodies in Two Pregnancies Without Evidence of Fetal Infection: A Case Report and Challenges in Serological Interpretation
Another well-documented source of interference is rheumatoid factor, an autoantibody found in people with rheumatoid arthritis and some other conditions. Rheumatoid factor belongs to the IgM class and can bind to rubella-specific IgG already in the blood, creating a false signal that mimics rubella IgM. Research has shown that even moderate levels of rheumatoid factor can produce false-positive rubella IgM results, particularly if the person has high rubella IgG levels from past vaccination or infection.3PubMed Central. IgM-class rheumatoid factor interference in the solid-phase radioimmunoassay of rubella-specific IgM antibodies Labs can remove this interference by pretreating the sample, but not every lab does so routinely.
Avidity Testing to Sort Out Ambiguous Results
When a rubella IgM test comes back positive and there is any clinical suspicion of recent infection, particularly in a pregnant woman, labs often turn to IgG avidity testing to get a clearer picture. Avidity refers to how tightly antibodies bind to the virus. Early in an infection, the immune system produces IgG that binds weakly; over time, the body refines these antibodies so they grip the virus much more firmly. A test that measures this binding strength can tell the difference between an immune response that started recently and one that has been established for months or years.
Low avidity suggests the infection happened within the past few weeks, while high avidity points to an older infection or longstanding immunity. Research comparing avidity results against clinical records found that all samples with low IgG avidity came from people with confirmed acute primary rubella, and all samples with high avidity came from people with established immunity, including those who had experienced reinfection.4PubMed. Measurement of avidity of specific IgG for verification of recent primary rubella A separate study examined the timeline more precisely and found that avidity typically transitions from low to high around four weeks after the onset of symptoms, with values below about 30% indicating a recent primary infection and values above that pointing to a previous one.5PubMed. Rubella IgG total antibody avidity and IgG subclass-specific antibody avidity assay and their role in the differentiation between primary rubella and rubella reinfection
In the context of pregnancy, this distinction can change the entire course of clinical management. A pregnant woman with high-avidity IgG and a positive IgM can generally be reassured that the IgM is a false positive or a remnant of old immunity, not a sign of dangerous new infection. Avidity testing is not perfect, and borderline results do occur, but it is one of the most useful tools for avoiding unnecessary interventions based on misleading IgM results.
What a Positive Test Means During Pregnancy
Pregnancy is where the stakes of rubella testing are highest. Rubella itself is a mild illness in adults, often producing nothing more than a rash, mild fever, and joint pain. But when the virus crosses the placenta during early pregnancy, it can cause congenital rubella syndrome, a constellation of birth defects that can include heart defects, deafness, cataracts, and developmental delays.
The risk is heavily tied to timing. A landmark study tracking confirmed maternal rubella infections at different gestational stages found that the rate of congenital infection exceeded 80% when maternal rubella occurred during the first 12 weeks of pregnancy, dropped to about 54% at weeks 13 to 14, and fell to around 25% by the end of the second trimester before rising again late in pregnancy. Crucially, rubella defects appeared in all infants infected before week 11 and in about 35% of those infected between weeks 13 and 16, but no defects attributable to rubella were found in children infected after 16 weeks.6PubMed. Consequences of confirmed maternal rubella at successive stages of pregnancy The risk of serious harm is concentrated squarely in the first trimester, with risk dropping substantially after that window closes.
This is why prenatal screening focuses so intensely on rubella immunity. A positive IgG before or early in pregnancy typically means the mother is protected and the fetus is not at risk. The concern arises when IgG is absent, when IgM turns positive, or when IgG levels change between two blood draws in a way that suggests new infection. Even then, as discussed above, confirmatory testing with avidity assays is critical before any serious decisions are made.7PubMed. Rubella infection in pregnancy
Vaccine-Induced Immunity Versus Natural Immunity
If your positive rubella test reflects immunity from the MMR vaccine rather than a childhood infection, the character of that immunity is somewhat different. Research comparing the immune responses after natural rubella infection versus vaccination found measurable differences in IgG levels, IgM persistence, and avidity patterns between the two groups.8PubMed Central. Humoral immune response after primary rubella virus infection and after vaccination A long-term follow-up study of young adults found that people with naturally acquired immunity carried significantly higher antibody levels, with average titers roughly three times those of vaccinated individuals.9Vaccine. Long-term follow-up study of rubella antibodies in naturally immune and vaccinated young adults
Does that mean vaccine immunity is inadequate? Not necessarily. Lower antibody levels do not automatically translate into lack of protection, and the immune system has other layers of defense beyond circulating antibodies, including memory cells that can mount a rapid response on re-exposure. But it does explain why some vaccinated individuals can show borderline or low-positive IgG results years after vaccination, sometimes prompting confusion about whether they are actually protected. Research has identified a threshold of about 15 international units per milliliter (IU/mL) by ELISA as a practical cutoff; people with levels below this responded to revaccination as if they had never been vaccinated, suggesting their immunity had waned to the point of being functionally absent.10The Journal of Infectious Diseases. Serum Levels of Rubella Virus Antibodies Indicating Immunity: Response to Vaccination of Subjects with Low or Undetectable Antibody Concentrations
If your test shows a low-positive IgG and you are planning a pregnancy, your doctor may recommend a booster dose of MMR vaccine before conception. Since the vaccine contains live attenuated virus, it should not be given during pregnancy itself, which is why preconception planning matters.
Can You Get Rubella Twice?
Reinfection with rubella is possible but uncommon, and this is where test results can get especially confusing. People who have been vaccinated or previously infected can occasionally be re-exposed to wild rubella virus and mount a secondary immune response. In most cases the reinfection produces no symptoms and poses no risk, because the immune system catches the virus quickly. But in rare instances, reinfection during pregnancy has led to fetal infection.
A report from England and Wales described five cases of asymptomatic maternal reinfection during the mid-1980s that resulted in intrauterine infection. In four of the five cases, the mother caught rubella from her own children. Two pregnancies were terminated, with rubella virus recovered from the fetal tissue, and three infants were born with congenitally acquired disease.11British Medical Journal. Fetal infection after maternal reinfection with rubella: criteria for defining reinfection The risk associated with reinfection is considered very small compared to primary infection, but it is not zero. On a blood test, reinfection typically shows a rapid rise in IgG without the full IgM response you would see in a primary infection. The avidity of IgG remains high, because the immune system is building on an existing response rather than starting from scratch. In the study mentioned earlier, women with confirmed reinfection during pregnancy had IgG avidity values ranging from 48% to 100%, clearly in the high range.5PubMed. Rubella IgG total antibody avidity and IgG subclass-specific antibody avidity assay and their role in the differentiation between primary rubella and rubella reinfection This is why avidity testing alone cannot rule out reinfection; it distinguishes primary infection from everything else, but “everything else” includes both safe old immunity and the rare reinfection.
Confirming Infection Beyond Antibodies
When serological tests leave room for doubt, the most definitive way to confirm rubella is to detect the virus itself. Molecular testing using RT-PCR (a method that amplifies viral genetic material) can identify rubella virus RNA in blood, throat swabs, urine, or, in the case of a newborn, various tissue samples. Newer multiplex assays have improved the sensitivity and efficiency of this detection, particularly for molecular surveillance and case confirmation where a rapid definitive answer matters.12PubMed. Improved diagnostic and multiplex RT-qPCR for detecting rubella viral RNA
For diagnosing congenital rubella syndrome in infants, both IgM detection and PCR play complementary roles. In a study of 65 infants with suspected congenital rubella syndrome, 40% were confirmed by detection of rubella-specific IgM, while PCR testing correlated well with serology and picked up additional cases. Among the specimens tested, lens tissue and oral fluid yielded the highest rates of virus detection.13PubMed. Laboratory confirmation of congenital rubella syndrome in infants: an eye hospital based investigation Interestingly, research on the fetal immune response found that newborns infected very early in pregnancy, during the first 12 weeks, showed significantly reduced antibody responses to certain rubella proteins, likely because the fetal immune system was too immature to mount a full response at the time of infection.14Journal of Medical Virology. The role of rubella-immunoblot and rubella-peptide-EIA for the diagnosis of the congenital rubella syndrome during the prenatal and newborn periods This means standard antibody tests can sometimes underdiagnose congenital rubella syndrome in the very infants at highest risk, making molecular confirmation even more important.
Why Rubella Testing Is Not Perfectly Standardized
One frustrating reality is that rubella antibody levels reported by different labs are not perfectly comparable. The tests are supposed to be calibrated against an international standard set by the World Health Organization, but an investigation into why results vary between assays found that the current WHO reference standard fails to meet key measurement principles, leading to discrepancies in reported IgG concentrations across different commercial test platforms.15Clin Microbiol Rev. Standardization of Assays That Detect Anti-Rubella Virus IgG Antibodies In practice, this means a result of 12 IU/mL on one lab’s machine might correspond to a different true antibody concentration than 12 IU/mL on another. For people near the protective threshold, this inconsistency can lead to conflicting results between tests.
If you have been told your rubella immunity is “equivocal” or borderline, this lack of standardization is part of the reason. It does not mean something is wrong with you; it may simply mean your antibody level sits in a gray zone where measurement uncertainty matters. Repeating the test or getting revaccinated are both reasonable responses, depending on your circumstances.
The Bigger Reason Rubella Testing Still Matters
You might wonder why rubella testing remains part of routine prenatal care when rubella has become so rare in many countries. The answer is that “rare” does not mean gone. Globally, rubella incidence fell by 81% between 2013 and 2021, and reported cases dropped from nearly 94,000 in 2012 to about 17,400 in 2022. As of that year, roughly 90% of WHO member countries had included rubella-containing vaccines in their national schedules, up from 68% a decade earlier.16Morbidity and Mortality Weekly Report. Progress Toward Rubella and Congenital Rubella Syndrome Elimination — Worldwide, 2012–2022 More than half of countries worldwide have been verified as having sustained rubella elimination.17PubMed Central. Global challenges and solutions to achieving and sustaining measles and rubella elimination
But elimination is verified country by country, and international travel means a pregnant woman in a low-circulation country can still be exposed through contact with someone from a region where rubella persists. Gaps in vaccination coverage, whether from access barriers, vaccine hesitancy, or disruptions like the COVID-19 pandemic, create pockets of susceptibility. Congenital rubella syndrome cases continue to be diagnosed even in countries with strong vaccination programs, often linked to mothers who were born abroad, missed vaccination, or had waning immunity.18PubMed Central. Congenital rubella syndrome, a case series Screening remains the best way to identify women who are not protected before a pregnancy puts them at risk.
Cost-Effective Screening in Practice
Given that most women in well-vaccinated populations will test positive for rubella IgG and need no further action, healthcare systems have explored ways to make screening more efficient. A cost-effectiveness analysis comparing different screening strategies found that using electronic medical record alerts to flag women who lacked documented rubella immunity was the most cost-effective approach, at a fraction of a cent per quality-adjusted life year, far below conventional cost-effectiveness thresholds.19PubMed Central. Cost-effectiveness analysis of rubella screening strategies using electronic medical records The practical takeaway is that systems are moving toward targeted screening rather than universal retesting, which means your rubella result from a prior pregnancy or a documented vaccination record may carry forward without repeating the blood draw. If you are asked to get tested again, it usually means your records do not show a prior positive or your doctor wants to confirm immunity has held.
For women found to be rubella-seronegative during pregnancy, vaccination cannot happen until after delivery, so the standard recommendation is to receive the MMR vaccine in the immediate postpartum period before hospital discharge. This protects any future pregnancies. If you are not pregnant and discover you lack rubella immunity, vaccination now saves the anxiety of dealing with uncertain test results later.